Select Mergers & Acquisitions and Strategic Collaborations

  • Represented Tidal Therapeutics, Inc. as interim CBO in $470 million acquisition by Sanofi.
  • Represented Torque Therapeutics, Inc. in a merger with Cogen Therapeutics, Inc. and creation of a new company, Repertoire Immune Medicines, Inc.
  • Advised Voyager Therapeutics, Inc. on its research and license option agreement with Abbvie Inc. to develop vectorized Tau antibodies for treatment of Alzheimer’s disease and other tauopathies with $69 million upfront and up to $1.2 billion in milestones.
  • Advised Voyager Therapeutics, Inc. in connection with negotiation of restructuring of gene therapy collaboration with Sanofi where Voyager gains worldwide rights to the Huntington’s disease program and ex-U.S. rights to the Friedreich’s ataxia program, and Sanofi obtains exclusive option rights to select novel AAV capsids owned or controlled by Voyager for exclusive use for up to two non-central nervous system (non-CNS) indications.
  • Represented Broadwing Bio, Inc. in an option and asset sale of Glaucoma program and IP to large pharma.
  • Represented Notch Therapeutics, Inc. in a research collaboration, licensing agreement to develop iPSC-derived allogeneic cell therapies for hematologic cancers for up to $1 billion, and equity investment by Allogene Therapeutics, Inc.
  • Represented Arovella Therapeutics in a divestiture of nasal spray business and asset sale of Perth facility.
  • Represented Arovella Therapeutics in a collaboration with Imugene to combine iNKT CD19 cell therapy with oncolytic vaccine (terms undisclosed).
  • Advised Arovella Therapeutics on in-license option to IL-12 cytokine technology from University of North Carolina.
  • Advised Arovella Therapeutics on in-licensing of CAR iNKT CD19 cell therapy program and iNKT cell therapy platform from Imperial College London.
  • Represented Torque Therapeutics, Inc. in the manufacturing collaboration and co-investment with Thermo Fisher Scientific, Inc. to build cell therapy manufacturing facility for clinical and commercial product supply.
  • Advised Iveric Bio on the in-licensing of retinitis pigmentosa gene therapy program from University of Florida and University of Pennsylvania.

Public and Private Financings

  • Advised Apogee Therapeutics, Inc. in the $345 million IPO.
  • Advised Adagio Therapeutics, Inc. in the $300 million IPO.
  • Advised Adagio Therapeutics, Inc. in the $336 million series C financing.
  • Represented Torque Therapeutics, Inc. in the $70 million series B financing.
  • Advised Tscan Therapeutics, Inc. in connection with the $150 million upsized follow-on public offering.
  • Advised Repertoire Immune Medicines, Inc. in the $189 million crossover financing.
  • Advised Voyager Therapeutics, Inc. on the $58 million follow-on public offering.
  • Represented ADRX, Inc. in the series A financing extension.